Special Issue "Study on Drug—Bee Venom Interactions"

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Animal Venoms".

Deadline for manuscript submissions: 31 January 2022.

Special Issue Editor

Prof. Dr. Woojin Kim
E-Mail Website
Guest Editor
Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul, Korea
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Thanks to previously published studies, the therapeutic effects of bee venom and its subcomponents, such as melittin and phospholipase A2, are relatively well known. To list a few examples, neuropathic pain, progressive muscle atrophy, idiopathic Parkinson’s disease, and cancers were all shown to be attenuated by bee venom administration. Furthermore, their mechanisms of action are also beginning to be clarified. However, in order for bee venom to be widely used against different types of diseases, its interaction with conventionally used drugs must be understood; thus far, the effects of their interactions have been poorly investigated.

Thus, this Special Issue of Toxins is devoted to understanding the interactions of bee venom and its subcomponents (i.e., apamin, melittin, phospholipase A2, etc.) with other drugs used to treat various diseases. We welcome all research focused on the combination effect of bee venom and other conventionally used drugs (i.e., anti-analgesic, anti-inflammatory, anti-cancerogenic drugs). Bee venom and drugs could be treated simultaneously or sequentially. In vivo and in vitro studies are all welcomed. Topics of interest include, but are not limited to, the following: bee venom; cancers; pain (neuropathic pain); immunology; and neuromodulation.

Prof. Dr. Woojin Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • apamin
  • bee venom
  • combination treatment
  • drugs
  • drug interactions
  • mechanism of effects

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Effect of Combined Bee Venom Acupuncture and NSAID Treatment for Non-Specific Chronic Neck Pain: A Randomized, Assessor-Blinded, Pilot Clinical Trial
Toxins 2021, 13(7), 436; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13070436 - 23 Jun 2021
Viewed by 733
This study aimed to investigate the feasibility of a combined treatment of bee venom acupuncture (BVA) and non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of non-specific chronic neck pain (NCNP). Patients with NCNP for ≥3 months were randomly allocated to a BVA, NSAIDs, [...] Read more.
This study aimed to investigate the feasibility of a combined treatment of bee venom acupuncture (BVA) and non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of non-specific chronic neck pain (NCNP). Patients with NCNP for ≥3 months were randomly allocated to a BVA, NSAIDs, or combined group (1:1:1), receiving 6 sessions of BVA, loxoprofen (180 mg daily), or a combination, respectively, for 3 weeks. Recruitment, adherence, and completion rates were calculated to assess feasibility. Bothersomeness, pain, disability, quality of life, depressive status, treatment credibility, and adverse events were assessed. In total, 60 participants were enrolled, and 54 completed the trial. Recruitment, adherence, and completion rates were 100%, 95%, and 90%, respectively. Bothersomeness, pain, disability, and depressive symptoms significantly improved in all groups after treatment (p < 0.05). The combined group showed continuous improvement during the follow-up period (p < 0.05). Quality of life was significantly improved (p < 0.05), and treatment credibility was maintained in the BVA and combined groups. No serious adverse events were reported. Combined treatment of BVA and NSAIDs are feasible for the treatment of NCNP, showing high persistence of the effect, credibility, and safety. Additional trials with longer follow-up are needed to confirm this effect. Full article
(This article belongs to the Special Issue Study on Drug—Bee Venom Interactions)
Show Figures

Figure 1

Back to TopTop